Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5%. In this regard, the company has enclosed a press release on 5th May 2021.
The above information is a part of company’s filings submitted to BSE.